Literature DB >> 12182887

Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice.

K Spittaels1, C Van den Haute, J Van Dorpe, D Terwel, K Vandezande, R Lasrado, K Bruynseels, M Irizarry, M Verhoye, J Van Lint, J R Vandenheede, D Ashton, M Mercken, R Loos, B Hyman, A Van der Linden, H Geerts, F Van Leuven.   

Abstract

Glycogen synthase kinase-3beta (GSK-3beta) is important in neurogenesis. Here we demonstrate that the kinase influenced post-natal maturation and differentiation of neurons in vivo in transgenic mice that overexpress a constitutively active GSK-3beta[S9A]. Magnetic resonance imaging revealed a reduced volume of the entire brain, concordant with a nearly 20% reduction in wet brain weight. The reduced volume was most prominent for the cerebral cortex, without however, disturbing the normal cortical layering. The resulting compacted architecture was further demonstrated by an increased neuronal density, by reduced size of neuronal cell bodies and of the somatodendritic compartment of pyramidal neurons in the cortex. No evidence for apoptosis was obtained. The marked overall reduction in the level of the microtubule-associated protein 2 in brain and in spinal cord, did not affect the ultrastructure of the microtubular cytoskeleton in the proximal apical dendrites. The overall reduction in size of the entire CNS induced by constitutive active GSK-3beta caused only very subtle changes in the psychomotoric ability of adult and ageing GSK-3beta transgenic mice. Copyright 2002 IBRO

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182887     DOI: 10.1016/s0306-4522(02)00236-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  44 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

Review 2.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

Review 3.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 4.  GSK3 signalling in neural development.

Authors:  Eun-Mi Hur; Feng-Quan Zhou
Journal:  Nat Rev Neurosci       Date:  2010-08       Impact factor: 34.870

5.  Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.

Authors:  Jos Prickaerts; Dieder Moechars; Kim Cryns; Ilse Lenaerts; Hansfried van Craenendonck; Ilse Goris; Guy Daneels; J Adriaan Bouwknecht; Thomas Steckler
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

Review 6.  Circadian genes, rhythms and the biology of mood disorders.

Authors:  Colleen A McClung
Journal:  Pharmacol Ther       Date:  2007-02-28       Impact factor: 12.310

7.  Molecular mechanism of size control in development and human diseases.

Authors:  Xiaolong Yang; Tian Xu
Journal:  Cell Res       Date:  2011-04-12       Impact factor: 25.617

8.  GSK-3 modulates SHH-driven proliferation in postnatal cerebellar neurogenesis and medulloblastoma.

Authors:  Jennifer K Ocasio; Rolf Dale P Bates; Carolyn D Rapp; Timothy R Gershon
Journal:  Development       Date:  2019-10-10       Impact factor: 6.868

9.  MyosinV controls PTEN function and neuronal cell size.

Authors:  Michiel T van Diepen; Maddy Parsons; C Peter Downes; Nicholas R Leslie; Robert Hindges; Britta J Eickholt
Journal:  Nat Cell Biol       Date:  2009-09-20       Impact factor: 28.824

10.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Authors:  Oksana Kaidanovich-Beilin; Tatiana V Lipina; Keizo Takao; Matthijs van Eede; Satoko Hattori; Christine Laliberté; Mustafa Khan; Kenichi Okamoto; John W Chambers; Paul J Fletcher; Katrina MacAulay; Bradley W Doble; Mark Henkelman; Tsuyoshi Miyakawa; John Roder; James R Woodgett
Journal:  Mol Brain       Date:  2009-11-19       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.